Holders are advised that the Issuer has published its Unaudited Interim Financial Statements for the six-month period ended 30 June 2024 (the ‘IFS’) ...
Key events during Q2 2024 During the first half of 2024, ChromoGenics continued its developmental journey with a strong focus on the customer and quality, continued to take measures to lower costs, an ...